Eli Lilly and Company (LLY) Stock Price, Quote & News

Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 317 276 2000

Website: www.lilly.com

Address:

Lilly Corporate Center, Indianapolis, United States

Catamount May. 13 at 12:00 PM

$LLY

0 · Reply

LLYBULL May. 13 at 10:55 AM

$LLY Zepbound/Mounjaro with Foundayo is the best combo in market for weightloss and maintenance.

0 · Reply

ToxicAvenger May. 13 at 10:48 AM

$LLY hit 1200 the split em...

0 · Reply

Richynr1 May. 13 at 6:14 AM

$NVO $LLY

0 · Reply

Richynr1 May. 13 at 6:12 AM

$NVO $LLY sponsoring articles to help offload $1.5 billion in stock for which there is no demand

0 · Reply

mikesterz7 May. 13 at 1:40 AM

$LLY The clinical data address a major unmet need in obesity treatment: preventing weight regain once patients step down from higher doses or switch therapies.

0 · Reply

Abemeister May. 13 at 12:34 AM

$LLY where will LLY be by Friday now?

0 · Reply

StocktwitsNews May. 13 at 12:22 AM

Eli Lilly Clinical Trial Shows Its Obesity Drugs Can Cause Weight Loss And Help Maintain It $LLY $VTI $VOO https://stocktwits.com/news/equity/markets/eli-lilly-clinical-trial-shows-its-obesity-drugs-can-cause-weightloss-and-help-maintenance/cZXLGjwRe02

0 · Reply

rigged69 May. 12 at 11:35 PM

$HIMS $SLS $LLY $JNJ

0 · Reply

dewmoore May. 12 at 10:34 PM

$SLS We’ve been averaging 1.34 events per month since that December update— But honestly that "78 events as of May 11" might already be old news. Don’t sleep on the verification lag. Reporting cutoffs are notorious for missing real-time data, especially over weekends. Between the site notification and CRO sign-off, the 80th event could literally be "in the mail" while the market trades off old numbers. People think long trials mean a steady drip, but "clusters" are a statistical reality. You get a group of patients hitting the same fragile wall at the exact same time after years of survival. One bad weekend could trigger the whole final analysis. The math says we hit 80th in late June, but with verified events potentially hidden behind the cutoff, we could easily hit the 80th before the shareholder vote. I’m holding my vote until the literal last minute—no sense in showing cards before the data clears the air. $MRK $LLY $PFE

0 · Reply

Eli Lilly launches Alzheimer's drug Donanemab in India

2026-05-12T22:17:46.000Z - 14 hours ago

Eli Lilly discloses results on Foundayo and lower-dose Zepbound

LLY

May 12, 2026, 6:03 PM EDT - 14 hours ago

Patients don't regain much weight switching from injections to Lilly's weight-loss pill, study finds

May 12, 2026, 6:01 PM EDT - 14 hours ago

Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials

May 12, 2026, 12:00 PM EDT - 20 hours ago

In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries

2026-05-12T12:55:59.000Z - 23 hours ago

Roche receives CE Mark for Elecsys pTau217

LLY

May 11, 2026, 3:14 PM EDT - 1 day ago

Exclusive: Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

May 11, 2026, 8:55 AM EDT - 1 day ago

NYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific Innovation

ICE

May 10, 2026, 2:30 PM EDT - 2 days ago

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

EW ISRG NTRA NVO

May 8, 2026, 8:58 AM EDT - 4 days ago

Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake

2026-05-08T11:39:44.000Z - 5 days ago

Eli Lilly price target raised to $1,235 from $1,183 at Guggenheim

LLY

May 7, 2026, 8:15 AM EDT - 6 days ago

Novo and Lilly gain on signs weight-loss pills could expand the market

NVO

May 7, 2026, 5:30 AM EDT - 6 days ago

Heard on the Street: The fastest-growing part of the weight-loss market—and perhaps the most underappreciated driver for both Novo Nordisk and Lilly—is outside the U.S.

NVO

2026-05-07T05:01:38.000Z - 6 days ago

Eli Lilly commits additional $4.5B across Indiana manufacturing sites

LLY

May 6, 2026, 9:09 AM EDT - 6 days ago

Lilly commits additional $4.5 billion across Indiana manufacturing sites

May 6, 2026, 9:00 AM EDT - 6 days ago

Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility

May 6, 2026, 6:12 AM EDT - 7 days ago

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly.

May 6, 2026, 5:35 AM EDT - 7 days ago

The Billion-Dollar Women's Health Market Driving A New Endometriosis Focus

NVO

2026-05-05T11:20:12.000Z - 8 days ago

Eli Lilly announces new long-term Omvoh data

LLY

May 5, 2026, 6:45 AM EDT - 8 days ago

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

2026-05-05T09:01:51.000Z - 8 days ago

Eli Lilly price target raised to $1,400 from $1,350 at Barclays

LLY

May 4, 2026, 11:11 AM EDT - 8 days ago

Lilly declares second-quarter 2026 dividend

2026-05-04T14:23:19.000Z - 8 days ago

Eli Lilly tells RBC liver case ‘not reasonably related to Foundayo’

LLY

2026-05-04T14:11:21.000Z - 8 days ago

Eli Lilly fears for Foundayo ‘unfounded,’ says Wolfe Research

LLY

May 4, 2026, 9:48 AM EDT - 8 days ago

FDA Reports Liver Failure in Patient Taking Lilly's Foundayo

2026-05-04T12:53:23.000Z - 8 days ago

Eli Lilly falls after FDA reports death of patient taking Foundayo

LLY

2026-05-04T12:42:46.000Z - 8 days ago

Evercore says report in FAERS has ‘potential to create confusion’ for Eli Lilly

LLY

May 4, 2026, 6:45 AM EDT - 9 days ago

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

NVO

2026-05-01T16:06:34.000Z - 11 days ago

Eli Lilly price target raised to $1,344 from $1,327 at Morgan Stanley

LLY

2026-05-01T14:42:55.000Z - 11 days ago

Eli Lilly price target raised to $1,230 from $1,205 at Cantor Fitzgerald

LLY

May 1, 2026, 10:03 AM EDT - 11 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

ABBV BMY GILD GSK

May 1, 2026, 6:52 AM EDT - 12 days ago

Lilly's obesity pill hits 5,612 prescriptions in third week after launch

Apr 30, 2026, 11:16 AM EDT - 12 days ago

Demand for Weight-Loss Drugs Drove Blockbuster Results for Eli Lilly. Its Stock Is Surging.

Apr 30, 2026, 11:06 AM EDT - 12 days ago

Eli Lilly CEO on new GLP-1 pill: It's been out 20 days and we have over 20,000 patients

Apr 30, 2026, 11:02 AM EDT - 12 days ago

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

NVO

Apr 30, 2026, 10:24 AM EDT - 12 days ago

QCOM Rally, RCL Regains Bookings Pace, LLY Soars

QCOM RCL

Apr 30, 2026, 9:54 AM EDT - 12 days ago

US FDA proposes excluding weight-loss drugs from compounding list

NVO

Apr 30, 2026, 8:17 AM EDT - 13 days ago

More than 20,000 people are taking Eli Lilly's weight loss pill, CEO says

Apr 30, 2026, 8:08 AM EDT - 13 days ago

Eli Lilly cemented its lead in the booming weight-loss drug market with huge sales gains for the first quarter, as focus shifts to new pills

Apr 30, 2026, 7:19 AM EDT - 13 days ago

Eli Lilly stock jumps 6% after strong earnings and raised guidance

Apr 30, 2026, 7:08 AM EDT - 13 days ago

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket

Apr 30, 2026, 6:58 AM EDT - 13 days ago

Lilly's stock rallies as sales of GLP-1 drugs nearly double

Apr 30, 2026, 6:51 AM EDT - 13 days ago

Eli Lilly raises annual profit forecast as GLP-1 drugs fuel growth

Apr 30, 2026, 6:45 AM EDT - 13 days ago

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines

Apr 30, 2026, 6:15 AM EDT - 13 days ago

Eli Lilly will report first quarter earnings before the bell. Here's what Wall Street expects

Apr 29, 2026, 1:47 PM EDT - 13 days ago

Here's How Much Traders Expect Eli Lilly Stock To Move After Earnings

Apr 29, 2026, 6:02 AM EDT - 14 days ago

Eli Lilly investors are eager for Foundayo insight after early launch data

Apr 28, 2026, 7:18 AM EDT - 15 days ago

Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion

Apr 28, 2026, 2:03 AM EDT - 15 days ago

Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial

NVO

Apr 27, 2026, 12:55 PM EDT - 15 days ago

Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs

AMGN NVS

Apr 27, 2026, 9:48 AM EDT - 15 days ago

As Investors Focus on Lilly's Foundayo, They May Be Overlooking Another Key Catalyst

Apr 27, 2026, 7:51 AM EDT - 16 days ago

Eli Lilly to Buy Ajax Therapeutics for Up to $2.3 Billion

Apr 27, 2026, 6:55 AM EDT - 16 days ago

Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion

Apr 27, 2026, 6:45 AM EDT - 16 days ago

Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera

Apr 24, 2026, 2:18 PM EDT - 18 days ago

Lilly stock falls as Foundayo trails Novo's Wegovy in early uptake

Apr 24, 2026, 8:14 AM EDT - 19 days ago

Lilly's obesity pill hits nearly 4000 prescriptions in second week after launch

Apr 23, 2026, 1:00 AM EDT - 20 days ago

‘BUYING OPPORTUNITIES': Investor reveals TOP stock picks amid uncertainty

HOOD META

Apr 22, 2026, 2:42 PM EDT - 20 days ago

Eli Lilly Is More Than GLP-1 Drugs. The Stock Looks Attractive.

Apr 21, 2026, 1:54 PM EDT - 21 days ago

Health insurers raise questions about Medicare program that will offer GLP-1s to seniors for $50

CVS NVO UNH

Apr 20, 2026, 4:47 PM EDT - 22 days ago

Monday's Final Takeaways: LLY New Acquisition & AAL Shuts Down UAL Bid

AAL UAL

Apr 20, 2026, 11:26 AM EDT - 22 days ago

Eli Lilly to buy Kelonia Therapeutics in up to $7 billion cancer immunotherapy drug deal

Catamount May. 13 at 12:00 PM

$LLY

0 · Reply

LLYBULL May. 13 at 10:55 AM

$LLY Zepbound/Mounjaro with Foundayo is the best combo in market for weightloss and maintenance.

0 · Reply

ToxicAvenger May. 13 at 10:48 AM

$LLY hit 1200 the split em...

0 · Reply

Richynr1 May. 13 at 6:14 AM

$NVO $LLY

0 · Reply

Richynr1 May. 13 at 6:12 AM

$NVO $LLY sponsoring articles to help offload $1.5 billion in stock for which there is no demand

0 · Reply

mikesterz7 May. 13 at 1:40 AM

$LLY The clinical data address a major unmet need in obesity treatment: preventing weight regain once patients step down from higher doses or switch therapies.

0 · Reply

Abemeister May. 13 at 12:34 AM

$LLY where will LLY be by Friday now?

0 · Reply

StocktwitsNews May. 13 at 12:22 AM

0 · Reply

rigged69 May. 12 at 11:35 PM

$HIMS $SLS $LLY $JNJ

0 · Reply

dewmoore May. 12 at 10:34 PM

0 · Reply

Catamount May. 12 at 10:28 PM

$LLY WTF is this?!? Are you serious? Lilly pays its employees extremely well, with phenomenal benefits, which includes a pension.

0 · Reply

focafoca99 May. 12 at 10:10 PM

$LLY revealed trial data showing patients maintained weight loss with oral Foundayo and lower-dose Zepbound after switching from higher-dose https://www.rapidticker.com/news/lly-lillys-foundayo-and-lower-dose-4cfcbf

0 · Reply

ripster47 May. 12 at 9:49 PM

Beautiful $LLY $UNH longs while market dumps! 🔥 Market bleeding today, but $UNH & $LLY were perfect trades from Day2 game plan! We had bullish bias going in - both held trend all day. All-day @ripster47 EMA cloud riders! 🎯

0 · Reply

Hga0 May. 12 at 8:17 PM

$LLY Now listen, you rich people, weep and wail because of the misery that is coming on you. 2 Your wealth has rotted, and moths have eaten your clothes. 3 Your gold and silver are corroded. Their corrosion will testify against you and eat your flesh like fire. You have hoarded wealth in the last days. 4 Look! The wages you failed to pay the workers who mowed your fields are crying out against you. The cries of the harvesters have reached the ears of the Lord Almighty. 5 You have lived on earth in luxury and self-indulgence. You have fattened yourselves in the day of slaughter.[a] 6 You have condemned and murdered the innocent one, who was not opposing you.

0 · Reply

BioRich May. 12 at 8:12 PM

$GUTS Summary: * Q1 2026 net income of $9.2 million versus $23.7 million loss in 2025 * R&D expenses decreased to $15.6 million from $19.4 million year-over-year * Adjusted EBITDA loss narrowed to $18.0 million from $23.0 million * Operating expenses $3.9 million lower year-over-year in Q1 2026 * Cash and equivalents of $6.2 million with runway into early 2027 * REMAIN-1 Pivotal Cohort randomization completed, pivotal data expected early Q4 2026 * FDA feedback indicates Revita DMR safety profile consistent with Class II device classification (DeNovo Path to approval) * CTA authorization in Netherlands enables first-in-human RJVA-001 study in T2D in 2026 This is excellent news for $GUTS. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI $BSX $LLY $NVO

1 · Reply

focafoca99 May. 12 at 7:10 PM

$LLY launches a 150th‑anniversary initiative to fund 500,000 meals and cold‑storage equipment for 150 food pantries nationwide. https://www.rapidticker.com/news/lly-in-honor-of-its-150th-be8b11

0 · Reply

GettnFibbywIT May. 12 at 6:42 PM

$LLY $XLV $IHE LLY / Daily Chart...On the 5/8/26 pullback, LLY is holding the 38.2% Fibonacci retracement with daily momentum stabilizing at the RSI 50 boundary — maintaining a bullish‑regime posture and avoiding a momentum breakdown. This makes the pullback constructive rather than structurally damaging. Upside, the $992, $1003, and $1018 levels remain the next technical areas of importance, where price and rising momentum would need to push and close above to continue building a bullish structural case:

1 · Reply